Picture loading failed.

Anti-CD19 therapeutic antibody (Pre-made Tafasitamab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-543-1mg 1mg 3090
GMP-Bios-ab-543-10mg 10mg 21890
GMP-Bios-ab-543-100mg 100mg 148000
GMP-Bios-ab-543-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CD19 therapeutic antibody (Pre-made Tafasitamab biosimilar,Whole mAb)
INN Name Tafasitamab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesMorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor
Conditions ApprovedDiffuse large B cell lymphoma
Conditions ActiveChronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma
Conditions Discontinuedna
Development TechMorphoSys HuCAL Phage Display;XmAb Engineering Technology